-

New Sample Preparation System Improves Proteomics Research Productivity

Thermo Scientific AccelerOme Automated Sample Preparation Platform brings greater reproducibility and standardization to LC-MS workflows

MINNEAPOLIS--(BUSINESS WIRE)--ASMS 2022 - Thermo Fisher Scientific Inc., the world leader in serving science, is helping proteomics researchers increase productivity and free up time for more value-added activities when generating high quality samples for analysis, using a new automated sample preparation system that integrates within any LC-MS workflow.

The Thermo Scientific AccelerOme Automated Sample Preparation Platform eliminates the need for labor-intensive, manual sample preparation for LC-MS analysis, including the associated method development and reagent sourcing. This allows users to focus on higher value tasks. Automated sample preparation also overcomes the challenge of maintaining reproducibility with manual methodologies, and the new platform’s pre-built validated methods and kit format reagents reduce further any risk of user error. The resulting peptide samples are of consistent high-quality. A novel built-in UV measurement of final peptide concentration prior to LC-MS analysis allows the standardization of sample peptide input for LC-MS analysis, another metric that adds to the quality, reliability and robustness of the final experimental result. The platform supports the use of peptide standards to monitor LC-MS system performance, enabling instrument health monitoring during acquisition or through post-acquisition data analysis.

Thermo Fisher Scientific is showcasing the AccelerOme Automated Sample Preparation Platform during the 70th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held June 5-9, 2022 in Booth 400 at the Minneapolis Convention Center, Minneapolis, Minnesota and at the Hilton Minneapolis Grand Ballrooms E, F, G.

“Proteomics researchers in academia and biopharma face an array of challenges, especially demands for speed and productivity,” said Andreas Huhmer, senior marketing director, omics research, life sciences mass spectrometry, Thermo Fisher Scientific. “Appropriate automated sample preparation systems for LC-MS have a crucial role. They provide support for core facilities, where flexibility and reproducibility are essential. In research labs, sample preparation systems are necessary to help to automate complex samples and large sample sets in order to rapidly generate rigorous data for publication, and in biopharma, these systems offer speed and productivity in commercialization. The AccelerOme platform provides a solution for proteomics LC-MS workflows.”

The AccelerOme sample preparation platform, designed with a unique experimental design tool, combines reliable and reproducible hardware with easy-to-use software and commercially available reagent kits for both label-free and TMT multiplexing applications. A software wizard guides users through each step, facilitating proteomics research to newcomers to the field. The new platform is optimized to fit into the Thermo Scientific Orbitrap MS ecosystem. End-to-end software, sample and study factor information are transferred from sample input all the way through to LC-MS acquisition through data analysis with Thermo Scientific Proteome Discoverer Software.

For more information on the Thermo Fisher solutions exhibited at ASMS 2022, please visit www.thermofisher.com/ASMS.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com

Janice Foley
BioStrata
+1 617-823-5555
jfoley@biostratamarketing.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
The Thermo Scientific AccelerOme Automated Sample Preparation Platform brings greater reproducibility and standardization to LC-MS workflows.
Release Versions

Contacts

Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com

Janice Foley
BioStrata
+1 617-823-5555
jfoley@biostratamarketing.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom